Polo Trial Pancreatic Cancer

Listing Websites about Polo Trial Pancreatic Cancer

Filter Type:

Maintenance Olaparib for Germline BRCA-Mutated …

(1 days ago) The POLO trial was a global trial, and when the trial was designed, 6-month treatment with FOLFIRINOX (fluorouracil, leucovorin, irinotecan, and oxaliplatin) was a standard of care. 2 Eligible

https://www.nejm.org/doi/full/10.1056/NEJMoa1903387

Category:  Cancer Show Health

Overall survival from the phase 3 POLO trial: Maintenance

(Just Now) 378. Background: POLO is the first phase 3 trial to evaluate maintenance therapy with the poly(ADP-ribose) polymerase inhibitor (PARPi) olaparib (O) in patients with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm) whose disease had not progressed on first-line platinum-based chemotherapy (PBC).POLO demonstrated that …

https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.378

Category:  Pancreatic cancer Show Health

POLO Trial - The ASCO Post

(7 days ago) In the POLO trial, which is discussed in this issue of The ASCO Post, Golan and colleagues evaluated the potential benefit of maintenance olaparib after disease stability or response to a minimum of 4 months of platinum-based chemotherapy in patients with metastatic pancreatic cancer and a

https://ascopost.com/issues/september-25-2019/polo-trial/

Category:  Pancreatic cancer Show Health

POLO: A randomized phase III trial of olaparib maintenance

(5 days ago) POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm). Talia Golan. x. Talia Golan. Search for articles by this author, Do-Youn Oh. x. Do-Youn Oh. Search for articles by this author

https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.TPS4152

Category:  Pancreatic cancer Show Health

POLO trial for advanced pancreatic cancer: a new standard

(4 days ago) Pancreatic cancer will soon become the second leading cause of cancer death in the United States. The randomized, double-blind, placebo-controlled phase III POLO trial focused on a selected group of patients with metastatic pancreatic cancer who had inherited mutations in the BRCA 1 and 2 genes. The study screened 3,315 patients at 119 centers

https://medicineworldcouncil.com/health-problems/polo-trial-for-advanced-pancreatic-cancer-a-new-standard-of-care/

Category:  Pancreatic cancer Show Health

POLO trial for advanced pancreatic cancer: a new …

(1 days ago) Pancreatic cancer will soon become the second leading cause of cancer death in the United States. The randomized, double-blind, placebo-controlled phase III POLO trial focused on a selected group

https://medicalxpress.com/news/2019-06-polo-trial-advanced-pancreatic-cancer.html

Category:  Pancreatic cancer Show Health

Making Sense of the Most Recent Data From the POLO Trial

(5 days ago) The POLO trial was a randomized, placebo-controlled, double-blind phase III trial of the PARP inhibitor olaparib vs placebo in patients with metastatic pancreatic cancer and a deleterious/suspected deleterious germline BRCA1/2 mutation (N = 154). Eligible patients had undergone ≥16 weeks of first-line platinum-based therapy (mainly FOLFIRINOX

https://www.clinicaloptions.com/oncology/programs/2021/parp-inhibition-pancreatic-cancer/clinicalthought/ct1/page-1

Category:  Pancreatic cancer Show Health

Geographic and Ethnic Heterogeneity of Germline BRCA1 …

(1 days ago) Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial J Clin Oncol . 2020 May 1;38(13):1442-1454. doi: 10.1200/JCO.19.01890.

https://pubmed.ncbi.nlm.nih.gov/32073954/

Category:  Pancreatic cancer Show Health

ASCO GI 2021: Results From the Phase 3 POLO Trial

(6 days ago) In the phase 3 POLO trial, Lynparza was evaluated against placebo as a maintenance therapy in patients with BRCA1 or BRCA2 mutation-positive metastatic pancreatic cancer. A total of 154 patients whose disease had not progressed during at least 16 weeks of first-line platinum-based chemotherapy were randomly assigned to receive either Lynparza

https://www.curetoday.com/view/asco-2021-results-from-the-phase-3-polo-trial

Category:  Pancreatic cancer Show Health

Lynparza approved in the EU for BRCA-mutated …

(9 days ago) Lynparza is approved in the US and several other countries as a 1st-line maintenance treatment for patients with gBRCAm metastatic pancreatic cancer based on the Phase III POLO trial, with ongoing regulatory reviews in other regions. Pancreatic cancer. Pancreatic cancer is a deadly cancer with a high unmet medical need.

https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-approved-in-the-eu-for-brca-mutated-metastatic-pancreatic-cancer.html

Category:  Pancreatic cancer Show Health

Cost-Effectiveness Analysis of Maintenance Olaparib in

(1 days ago) Objective: The phase III POLO trial demonstrated that olaparib as maintenance therapy for metastatic pancreatic cancer patients with a germline BRCA mutation had greater efficacy than placebo, but maintenance olaparib places an economic burden on patients. This study evaluated the cost-effectiveness of olaparib as maintenance therapy based on the POLO trial

https://pubmed.ncbi.nlm.nih.gov/33364840/

Category:  Pancreatic cancer Show Health

The role of PARP inhibitors in BRCA mutated pancreatic cancer

(3 days ago) Olaparib in pancreatic cancer. The data for the Pancreas Cancer Olaparib Ongoing (POLO) trial were presented at the plenary session of the American Society of Clinical Oncology (ASCO) 2019 meeting. The phase III randomized, double-blind controlled trial screened a total of 3315 patients with metastatic PDAC in 10 countries.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120537/

Category:  Pancreatic cancer Show Health

Maintenance Olaparib for Germline BRCA-Mutated Metastatic

(8 days ago) phase 3 POLO trial was conducted at 119 sites in 12 countries. With the use of a central interac- Olaparib for Metastatic Pancreatic Cancer maintenance olaparib tablets (300 mg twice daily) or

https://www.nejm.org/doi/pdf/10.1056/NEJMoa1903387?articleTools=true

Category:  Pancreatic cancer Show Health

Olaparib now approved for advanced pancreatic cancer

(8 days ago) The randomized, double-blind, placebo-controlled phase III POLO trial focused on a selected group of patients with metastatic pancreatic cancer who had inherited mutations in the BRCA 1 and 2 genes. The study screened 3,315 patients at 119 centers on 4 continents for germline BRCA mutations, which were detected in 7.5 percent of patients. After

https://www.uchicagomedicine.org/forefront/research-and-discoveries-articles/olaparib-now-approved-for-treating-advanced-pancreatic-cancer

Category:  Pancreatic cancer Show Health

POLO trial for advanced pancreatic cancer: a new standard

(4 days ago) As previously reported in At The Forefront on June 3, 2019. Treatment with the drug olaparib significantly reduced the risk of disease progression or death from metastatic pancreatic cancer, according to findings from the recently completed, international, phase-III POLO (Pancreas cancer OLaparib Ongoing) trial. Olaparib (trade name LYNPARZA, jointly …

http://medicine.uchicago.edu/polo-trial-for-advanced-pancreatic-cancer-a-new-standard-of-care/

Category:  Pancreatic cancer Show Health

Pancreatic Cancer Science—2021 in Review - Promising Science

(2 days ago) In the phase III POLO trial, olaparib was evaluated against a placebo as a maintenance therapy in patients with BRCA1 or BRCA2 mutation-positive metastatic pancreatic cancer. A total of 154 patients whose disease had not progressed during at least 16 weeks of first-line platinum-based chemotherapy were randomly assigned to receive either

https://letswinpc.org/promising-science/2021/12/29/pancreatic-cancer-science-2021-in-review/

Category:  Pancreatic cancer Show Health

POLO Trial Summary - Myriad MyRisk

(4 days ago) The POLO (Pancreas Cancer Olaparib Ongoing) trial was a randomized, double-blinded, placebo-controlled phase 3 trial aimed at assessing the efficacy of olaparib maintenance therapy in patients with a germline BRCA1/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed with first-line platinum-based chemotherapy. Patients

https://myriadmyrisk.com/polo-trial-summary/

Category:  Cancer Show Health

POLO trial for advanced pancreatic cancer: a new standard

(8 days ago) The randomized, double-blind, placebo-controlled phase III POLO trial focused on a selected group of patients with metastatic pancreatic cancer who had inherited mutations in the BRCA 1 and 2

https://www.newswise.com/articles/polo-trial-for-advanced-pancreatic-cancer-a-new-standard-of-care

Category:  Pancreatic cancer Show Health

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease

(7 days ago) Zhan M, Zheng H, Yang Y, He Z, Xu T, Li Q. Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial. Cancer Manag Res. 2020 Dec 16;12:12919-12926. doi: 10.2147/CMAR.S283169. eCollection 2020.

https://clinicaltrials.gov/ct2/show/NCT02184195

Category:  Pancreatic cancer Show Health

Olaparib may delay metastatic pancreatic cancer in patients

(9 days ago) The POLO trial (Pancreas Cancer Olaparib Ongoing) was designed to test whether olaparib is useful in treating metastatic pancreatic cancer after platinum-based chemotherapy. Between 5 and 10% of patients with pancreatic cancer have an inherited BRCA gene mutation. Researchers of this study wanted to know:

https://www.facingourrisk.org/XRAY/POLO-trial-olaparib-delays-pancreatic-cancer

Category:  Pancreatic cancer Show Health

Olaparib for BRCA mutant pancreas cancer: Should the POLO

(6 days ago) In clinical trials involving advanced pancreatic cancer chemotherapy, there have been reports that PFS can serve as a surrogate for OS. 4, 5 However, in the POLO trial, although the olaparib arm showed significantly longer PFS than the placebo arm, there was no difference in OS between the 2 groups, and this challenges the validity of the use

https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.32979

Category:  Pancreatic cancer Show Health

Maintenance Therapy With PARP Inhibitor Olaparib Delays

(1 days ago) The randomized, phase III POLO trial found that maintenance therapy with the PARP inhibitor olaparib (Lynparza) significantly delayed the progression of metastatic pancreatic cancer in patients with BRCA gene mutations compared with placebo (median progression-free survival: 7.4 months vs. 3.8 months, respectively).

https://www.asco.org/about-asco/press-center/news-releases/maintenance-therapy-parp-inhibitor-olaparib-delays-progression

Category:  Pancreatic cancer Show Health

Dr. Golan on the Phase III POLO Trial in BRCA-Mutant

(3 days ago) Talia Golan, MD, head of Sheba Pancreatic Cancer Center, discusses the results of the phase III POLO trial, which evaluated maintenance olaparib (Lynparza) c

https://www.youtube.com/watch?v=4-HIfyvtu-k

Category:  Pancreatic cancer Show Health

POLO trial for advanced pancreatic cancer: a new standard

(2 days ago) Pancreatic cancer will soon become the second leading cause of cancer death in the United States. The randomized, double-blind, placebo-controlled phase III POLO trial focused on a selected group

https://medicalxpress.com/pdf478772600.pdf

Category:  Pancreatic cancer Show Health

POLO Trial in Pancreatic Cancer

(Just Now) Advances in the Treatment of Pancreatic Cancer - Episode 12. POLO Trial in Pancreatic Cancer. July 24, 2019. EP. 1: Advanced Pancreatic Cancer and Molecular Testing.

https://www.onclive.com/view/polo-trial-in-pancreatic-cancer

Category:  Pancreatic cancer Show Health

Lynparza Passes Phase III Pancreatic Cancer Trial With

(8 days ago) The trial compared Lynparza (olaparib) to placebo. POLO is a Phase III randomized, double-blinded, placebo-controlled, multi-center trial of Lynparza tablets (300mg twice daily) alone compared to placebo. It randomized 154 patients with gBRCAm metastatic pancreatic cancer that had not progressed on first-line platinum-based chemotherapy.

https://www.biospace.com/article/astrazeneca-and-merck-s-lynparza-looks-good-in-pancreatic-cancer/

Category:  Pancreatic cancer Show Health

Israeli Oncologist Offers Hope With New Treatment For Some

(1 days ago) Dr. Golan’s POLO trial not only represents the progression of cancer treatment towards precision medicine, but offers “hope” and “time” to those with the most advanced form of pancreatic cancer, underscoring the importance of participating in clinical trials.

https://nocamels.com/2019/07/israeli-oncologist-hope-treatment-pancreatic-cancer/

Category:  Pancreatic cancer Show Health

Promising results for metastatic pancreatic cancer drug

(2 days ago) Dr. Talia Golan, head of the Pancreatic Cancer Center at Sheba Medical Center in Israel, has been conducting ongoing research and clinical trials with biopharmaceutical companies Astrazeneca and MSD (Merck) to evaluate the safety and test the efficacy of the POLO regimen.

https://www.israel21c.org/promising-results-for-metastatic-pancreatic-cancer-drug/

Category:  Pancreatic cancer Show Health

Phase III POLO Trial - Capsule Summary Slidesets - GI

(5 days ago) Phase III POLO trial of maintenance therapy with olaparib in patients with metastatic pancreatic cancer and germline BRCA mutation as …

https://www.clinicaloptions.com/oncology/conference-coverage/clin-onc-june-2019/gastrointestinal-cancers/capsule-summary-slidesets/lba4

Category:  Pancreatic cancer Show Health

Olaparib for Pancreatic Cancer with BRCA Mutations

(2 days ago) A targeted cancer drug already in use to treat some women with ovarian and breast cancer may also be beneficial for some people with advanced pancreatic cancer who have inherited mutations in the BRCA1 or BRCA2 genes, according to results from a large clinical trial.. In the clinical trial, called POLO, participants who received olaparib (Lynparza) following …

https://www.cancer.gov/news-events/cancer-currents-blog/2019/pancreatic-cancer-olaparib-brca-mutations

Category:  Pancreatic cancer Show Health

Lynparza significantly delayed disease progression as 1st

(3 days ago) POLO is a randomised, double-blinded, placebo-controlled trial exploring the efficacy of Lynparza tablets as 1st-line maintenance monotherapy in patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas (pancreatic cancer) whose disease has not progressed on platinum-based chemotherapy.

https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-significantly-delayed-disease-progression-as-1st-line-maintenance-treatment-in-germline-brca-mutated-metastatic-pancreatic-cancer-26022019.html

Category:  Pancreatic cancer Show Health

FDA Briefing Document Oncologic Drugs Advisory Committee

(1 days ago) The POLO trial required serial imaging with computerized tomography (CT) or magnetic resonance imaging (MRI) scans at baseline and for serial assessment pancreatic cancer, FDA approval of all

https://www.fda.gov/media/133539/download

Category:  Pancreatic cancer Show Health

Pancreatic cancer treatment: Polo trial for Maintenance

(3 days ago) Pancreatic cancer treatment 2019. During one of the plenary sessions of American Society of Clinical Oncology (ASCO) 2019 meeting in Chicago, recently, the POLO trial was described as the first trial to validate the use of maintenance Lynparza (olaparib) in pancreatic patients who harbour a germline BRCA 1/ 2 mutation.

https://www.pharmaceutical-technology.com/comment/pancreatic-cancer-treatment-2019/

Category:  Pancreatic cancer Show Health

Abstract CT217: POLO: Homologous - Cancer Research

(5 days ago) In summary, based on the subgroup of pts with analyzed tumor tissue, the genetic profile of the screened POLO population is reflective of that seen in the overall pancreatic cancer population. ~8% of pts had tumors harboring a BRCAm, with mutations in BRCA2 more prevalent than BRCA1; ~7% of pts had tumors harboring a non-BRCA HRRm, most commonly in ATM …

https://cancerres.aacrjournals.org/content/80/16_Supplement/CT217

Category:  Pancreatic cancer Show Health

Maintenance Olaparib in Elderly Patients With a Germline

(8 days ago) Abstract S-O3 - Kindler H, Hammel P, Reni M, et al. Maintenance olaparib in patients aged ≥65 years with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO Trial. ESMO World Congress on Gastrointestinal Cancer 2020 Virtual (1-4 July).

https://www.esmo.org/oncology-news/maintenance-olaparib-in-elderly-patients-with-a-germline-brca-mutation-and-metastatic-pancreatic-cancer

Category:  Pancreatic cancer Show Health

LYNPARZA® (olaparib) First-Line Maintenance Therapy Nearly

(Just Now) improve patient outcomes, pancreatic cancer remains an area of high unmet need. The results of the POLO trial may open the door to a new era of personalized, biomarker-led care in metastatic pancreatic cancer and reinforces the importance of knowing BRCA status at diagnosis.” The safety and tolerability profile of LYNPARZA in the POLO trial

https://www.merck.com/news/lynparza-olaparib-first-line-maintenance-therapy-nearly-doubled-the-time-without-disease-progression-or-death-in-phase-3-polo-trial-for-patients-with-germline-brca-mutated-metastatic-pancreati/

Category:  Pancreatic cancer Show Health

Predicting Benefit From Olaparib Maintenance in Metastatic

(6 days ago) The POLO study is a phase 3, randomized, controlled trial of olaparib monotherapy in 154 patients with metastatic pancreatic adenocarcinoma (with disease that had not progressed following first

https://www.cancertherapyadvisor.com/home/cancer-topics/pancreatic-cancer/predicting-benefit-from-olaparib-maintenance-in-metastatic-pancreatic-cancer-the-polo-trial/

Category:  Cancer Show Health

Olaparib Gains FDA Approval for Indication in Pancreatic

(6 days ago) In the randomized, double-blind, placebo-controlled POLO trial, investigators evaluated the efficacy of olaparib as maintenance therapy in 154 patients who had a germlineBRCA1orBRCA2mutation and metastatic pancreatic cancer, which had not progressed during first-line platinum-based chemotherapy.

https://www.targetedonc.com/view/olaparib-gains-fda-approval-for-indication-in-pancreatic-cancer

Category:  Pancreatic cancer Show Health

Incorporating PARP Inhibitors Into the Pancreatic Cancer

(1 days ago) The second strategy is exemplified by the Pancreas Cancer Olaparib Ongoing (POLO) trial. This was a phase III global trial that evaluated the impact of maintenance olaparib on the outcomes of patients with metastatic pancreatic cancer following initial treatment with platinum-based chemotherapy.

https://dailynews.ascopubs.org/do/10.1200/ADN.21.200507/full/

Category:  Pancreatic cancer Show Health

Efficacy – LYNPARZA® (olaparib)

(9 days ago) The POLO trial was a multicenter, double-blind, randomized, placebo-controlled phase 3 trial of LYNPARZA maintenance therapy in patients with gBRCA-mutated metastatic pancreatic cancer

https://www.lynparzahcp.com/metastatic-pancreatic-cancer/olaparib-efficacy.html

Category:  Pancreatic cancer Show Health

A trial of olaparib for pancreatic cancer that has spread

(Just Now) More about this trial. Doctors can treat pancreatic cancer that has spread, with chemotherapy. This won’t cure it but can slow the growth of the cancer. Researchers think that olaparib may also slow down the growth of pancreatic cancer that has an inherited change in BRCA1 or BRCA2. Healthy cells can repair themselves if they get damaged.

https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-olaparib-for-pancreatic-cancer-that-has-spread-polo

Category:  Pancreatic cancer Show Health

POLO Trial: Olaparib as a maintenance treatment following

(Just Now) Dr Teresa Macarulla talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about results from the phase III POLO trial - which assessed the use of olaparib as a maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA1/2 mutation and metastatic pancreatic cancer, compared …

https://ecancer.org/en/video/7972-polo-trial-olaparib-as-a-maintenance-treatment-following-first-line-chemotherapy-in-patients-with-metastatic-pancreatic-cancer

Category:  Pancreatic cancer Show Health

Israeli Study Finds Molecule That Triggers Self

(8 days ago) Dr. Golan is a lead researcher at the Pancreas Cancer Olaparib Ongoing (POLO) Clinical Trial at the Sheba Medical Center, working specifically with patients with advanced stages of pancreatic cancer as well as a BRCA 1 or 2 germline mutation. NoCamels reported on her work this summer, which offers a promising new drug regimen.

https://nocamels.com/2019/12/israeli-study-molecule-destruction-pancreatic-cancer-cells/

Category:  Pancreatic cancer Show Health

Comment: POLO III trial for metastatic pancreatic cancer

(9 days ago) Comment: POLO III trial for metastatic pancreatic cancer. ASCO 2019. 31 May - 4 Jun 2019. Please rate this video. In pancreas cancer we are missing very new targeted agents so this trial looked for patients who had a mutation in BRCA1 or BRCA2, germline. Only a few percentages of patients do have it but that may be very important for outcome.

https://ecancer.org/en/video/8008-comment-polo-iii-trial-for-metastatic-pancreatic-cancer

Category:  Pancreatic cancer Show Health

PARP Inhibitors Hit the Pancreatic Cancer Scene

(3 days ago) PARP inhibitors, which have approved indications in breast and ovarian cancer, are expanding to additional treatment paradigms, including pancreatic cancer. Data from the phase III POLO trial presented at the 2019 ASCO Annual Meeting showed that the PARP inhibitor olaparib (Lynparza) significantly improved progression-free survival (PFS

https://www.oncnursingnews.com/view/parp-inhibitors-hit-the-pancreatic-cancer-scene

Category:  Pancreatic cancer Show Health

Filter Type: